Epithalon vs Icotrokinra
Overview
Epithalon is primarily a sleep & recovery peptide, while Icotrokinra is used for immune support.
This page compares Epithalon and Icotrokinra across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Epithalon | Icotrokinra | |
|---|---|---|
| Category | Sleep & Recovery | Immune Support |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 5-10 mg | — |
| Frequency | cycle protocol | — |
| Reported benefits | Improved sleep quality, circadian rhythm regulation, anti-aging | — |
| Reported side effects | Minimal side effects during cycles | — |
Key differences
Primary use. Epithalon is categorised under Sleep & Recovery, while Icotrokinra falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Epithalon: not FDA-approved; compounding permitted with a prescription as of April 2026. Icotrokinra: FDA-approved.
Dosing. Epithalon is typically dosed at 5-10 mg (cycle protocol). Typical dosing for Icotrokinra is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking Epithalon and Icotrokinra has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Epithalon and Icotrokinra?
- Epithalon is primarily a sleep & recovery peptide, while Icotrokinra is used for immune support. Epithalon is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Icotrokinra is FDA-approved for one or more indications.
- What is Epithalon used for?
- Circadian rhythm regulator.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- Can you take Epithalon and Icotrokinra together?
- Some users combine peptides within a single protocol, but stacking Epithalon and Icotrokinra has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Epithalon or Icotrokinra FDA-approved?
- Epithalon is not FDA-approved; compounding permitted with a prescription (as of April 2026). Icotrokinra is FDA-approved for one or more indications.
Read the full articles
- Epithalon — full monograph: mechanism, research, dosing & references
- Icotrokinra — full monograph: mechanism, research, dosing & references